Salivary drug monitoring of irinotecan and its active metabolite in cancer patients

Cancer Chemotherapy and Pharmacology

Volumn 40, Issue 5, 1997, Pages 449-452

  Takahashi, Toshiaki ^a   Fujiwara, Yasuhiro ^a   Sumiyoshi, Hidetaka ^a   Isobe, Takeshi ^a   Yamaoka, Naoki ^a   Yamakido, Michio ^a  

^a HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

CPT 11; Saliva; SN 38; Therapeutic drug monitoring

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; DRUG METABOLITE; IRINOTECAN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG SALIVA LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; LUNG CANCER; MALE; PRIORITY JOURNAL;

AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; CAMPTOTHECIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SALIVA;

EID: 0030793176     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050685     Document Type: Article

References (24)

1. Abigerges D, Chabot GG, Armand J-P, Herait P, Gouyette A, Gandia D (1995) Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 13:210
2. Blanchard J, Harvey S, Morgan WJ (1991) Serum/saliva correlations for theophylline in asthmatics. J Clin Pharmacol 31:565
3. Bressolle F, Jacquet J-M, Galtier M, Jourdan J, Donadio D, Rossi J-F (1992) Doxorubicin and doxorubicinol plasma concentrations and excretion in parotid saliva. Cancer Chemother Pharmacol 30: 215
4. Burke TG, Mi A (1994) The structural basis of camptothecin interactions with human serum albumin: impact on drug sensitivity. J Med Chem 37:40
5. Chabot GG, Abigerges D, Catimel G, Culine S, De Forni M, Extra J-M, Mahjoubi M, Herait P, Armand J-P, Bugat R, Clavel M, Marty ME (1995) Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann Oncol 6:141
6. Conley BA, Egorin MJ, Zuhowski EG, Sinibaldi VJ, Peterson DE (1988) Salivary concentrations of hexamethylene bisacetamide (HMBA) in patients receiving 5-day continuous infusions. Cancer Chemother Pharmacol 22:65
7. De Forni M, Bugat R, Chabot GG, Culine S, Extra J-M, Gouyette A, Madelaine I, Marty ME, Mathieu-Boue A (1994) Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res 54:4347
8. Drobitch RK, Svensson CK (1992) Therapeutic drug monitoring in saliva. Clin Pharmacokinet 23:365
9. Gandia D, Abigerges D, Aramnd J-P, Chabot GG, Costa LD, De Forni M (1993) CPT-11-induced cholinergic effects in cancer patients. J Clin Oncol 11:196
10. Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE, Ratain MJ (1994) Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 54:3723
11. Haeckel R (1993) Factors influencing the saliva/plasma ratio of drugs. Ann NY Acad Sci 694:128
12. Kirk JK, Dupuis RE, Miles MV, Gaddy GD, Miranda-Massari JR, Williams DM (1994) Salivary theophylline monitoring: reassessment and clinical consideration. Ther Drug Monit 16:58
13. Kurono Y, Miyajima M, Ikeda K (1993) Interaction of camptothecin derivatives with human plasma proteins in vitro (in Japanese). Yakugaku Zasshi 113:167
14. Mick R, Gupta E, Vokes EE, Ratain MJ (1996) Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity. J Clin Oncol 14:2012
15. Negoro S, Fukuoka M, Masuda N, Takada M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S, Niitani H, Taguchi T (1991) Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small cell lung cancer. J Natl Cancer Inst 83:1164
16. Ohe Y, Sasaki Y, Shinkai T, Eguchi K, Tamura T, Kojima A, Kunikane H, Okamoto H, Karato A, Ohmatsu H, Kanzawa F, Saijo N (1992) Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion. J Natl Cancer Inst 84:972
17. Rothenberg ML, Kuhn JG, Burris HA, Nelson J, Eckardt JR, Tristan-Marales M, Hilsenbeck SG, Weiss GR, Smith LS, Rodriguez GI, Rock MK, Von Hoff DD (1993) Phase I pharmacokinetic trial of weekly CPT-11. J Clin Oncol 11:2194
18. Rowinsky EK, Grochow LB, Ettinger DS, Sartorius SE, Lubejko BG, Chen T-L, Rock MK, Donehower RC (1994) Phase I and pharmacological study of the novel topoisomearase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin (CPT-11) administered as a ninety-minutes infusion every 3 weeks. Cancer Res 54:427
19. Sasaki Y, Hakusui H, Mizuno S, Morita M, Miya T, Eguchi K, Shinkai T, Tamura T, Ohe Y, Saijo N (1995) A pharmacokinetic and pharmacodynamic analysis of CPT-11 and its active metabolite SN-38. Jpn J Cancer Res 86:101
20. Siegal IA, Ben-Aryeh H, Gozal D, Colin AA, Szargel R, Laufer D (1990) Comparison of unbound and total serum theophylline concentrations with those of stimulated and unstimulated saliva in asthmatic children. Ther Drug Monit 12:460
21. Slavik M, Wu J, Riley C (1993) Salivary excretion of anticancer drugs. Ann NY Acad Sci 694:319
22. Sumiyoshi H, Fujiwara Y, Ohashi N, Egusa Y, Yamaoka N, Yamakido M (1995) Clinical pharmacological evaluation of CPT-11 and cisplatin (CDDP) in patients with small cell lung cancer (SCLC) (abstract 1470). Proc Am Soc Clin Oncol 14:457
23. Sumiyoshi H, Fujiwara Y, Ohune T, Yamaoka N, Yamakido M (1995) High-performance liquid chromatographic determination of irinotecan(CPT-11) and its active metabolite (SN-38) in human plasma. J Chromatogr B 670:309
24. Yamaoka K, Tanigawara Y, Nakagawa T, Uno T (1981) A pharmacokinetic analysis program (MULTI) for microcomputer. J Pharmacobio-Dyn 4:879